Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.
about
A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumorsModification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cellsRe-purposing cancer therapeutics for breast cancer immunotherapyPreclinical HER-2 Vaccines: From Rodent to Human HER-2Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized miceSorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.Targeting the right regulatory T-cell population for tumor immunotherapy.PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.Impact of STAT1 and CD8+ T cells on the antineoplastic activity of lapatinib and doxorubicin against spontaneous mammary tumors.A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
P2860
Q33671350-B0118DC1-B7A2-4B8F-98D7-778120D85F0DQ35584127-7F0AE14E-19B5-4793-A437-FB8FE9F328CFQ35949083-EDDE41E6-5699-4577-B8E4-B3D15872FAC4Q36505831-6359C915-1530-4E6A-8BEF-990A77F0A4DDQ36638402-783E0F7B-A14E-42D1-B8F2-2BD6975C3241Q36914661-FE95F648-1B23-4403-9253-DF1F3617217CQ37725761-6DC00679-92A5-4433-B5CF-43FD7070C1EEQ38712735-01C19DFE-7EC8-4D18-81F2-FC18A9AEC088Q40510640-40D83CC6-58D5-4B3E-9331-4B1170B9E37AQ41274940-0C027DC9-DF2E-4C34-93D8-461EF642B472Q41931832-D7E7EA79-D7D2-4118-AE4A-3699AA1C0D5CQ41947450-82EC68A0-E39F-4D09-91C4-45CC2F17D7CFQ46094829-69629F19-5ED9-4DCE-A090-27AEEE23A33F
P2860
Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@ast
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@en
type
label
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@ast
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@en
prefLabel
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@ast
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@en
P2093
P2860
P356
P1476
Nondominant CD8 T cells are ac ...... ced antitumor immune response.
@en
P2093
Chelsea M Black
Emilee Flynn
Jennifer N Uram
Lanqing Huang
Todd D Armstrong
P2860
P304
P356
10.4049/JIMMUNOL.1000361
P407
P577
2011-02-23T00:00:00Z